Research infrastructure · Robotic cloud laboratories
Transcriptic
The first robotic cloud laboratory for the life sciences, started in 2012 by a Duke undergraduate who was tired of pressing a button on a plate reader. It became Strateos in 2019, ran Eli Lilly’s remote drug discovery lab, and has made no public announcement since April 2023.
The button on the plate reader
Max Hodak spent most of his time at Duke inside Miguel Nicolelis’s neural engineering lab. The science was what he wanted. The labor was not. He has described the moment the idea arrived as an accounting problem: “the sheer inefficiency of pressing a physical button on the plate reader every three hours for two days to gather the data I needed struck me pretty quickly.”
The fix came from the other side of his life. He had been programming since childhood. “Borrowing the metaphor from what cloud computing had done to software, the idea of creating a robotic cloud laboratory for biology seemed obvious.”
He graduated in May 2012 and founded Transcriptic that year. By December it had $1.2 million in seed money led by Google Ventures and FF Angel, with Mark Cuban and Naval Ravikant writing personal checks. Google Ventures general partner Wesley Chan said the technology had “the potential to impact biology in the same way that cloud computing has impacted information technology.”
The problem it was built for
Most wet lab biology is manual piecework, which makes it expensive, slow and hard to repeat. Hodak put it plainly in 2012: “Right now basic research is all done by hand, by grad students or lab techs standing at benches all day long doing really boring manual labor.” Transcriptic built shipping-container-sized enclosures it called work cells, packed them with instruments and a robotic arm, and wrapped them in a web interface and a scripting language called Autoprotocol.
In 2015 Hodak wrote that the company had “set out with the goal of giving the life sciences the same structural advantages that web has enjoyed, making it possible for two postdocs with a laptop in a coffee shop to run a drug company without the need for millions of dollars in capital equipment or lab space.”
Y Combinator, and the AWS analogy
In December 2014 Y Combinator gave its biotech companies $20,000 of free credit on Transcriptic and disclosed that Transcriptic was itself in the upcoming batch, Winter 2015. The post made the comparison that followed the company for a decade: “Transcriptic will hopefully do for biotech startups what AWS has done for web startups.” Money followed: $8.5 million in February 2015 led by Data Collective, then $13.4 million in November 2016 with Digital Science and WuXi AppTec joining. Hodak later wrote that he raised over $30 million across five years.
Three chief executives in seven years
Hodak stepped back in 2017 to co-found Neuralink. The handover is documented in an unlikely place, a Bionano Genomics proxy statement, which records that Yvonne Linney was Transcriptic’s chief operating officer from October 2015 and that “From January 2017 to November 2018, Dr. Linney served as the Chief Executive Officer” and a director through November 2018. Hodak’s own account is short: “I stepped down as CEO in 2017 to co-found Neuralink but remained involved with the company through early 2019 when it merged with 3scan and rebranded as Strateos.”
On June 3, 2019 the boards of Transcriptic and 3Scan, a 3D tissue imaging company, announced a merger. DCVC and Lux Capital put in another $16.5 million with support from Dolby Family Ventures. Mark Fischer-Colbrie, who ran Labcyte for a decade before Danaher bought it, became chief executive. Lux managing director Josh Wolfe said: “We are thrilled to help build a globally impactful and historic company.”
The Lilly lab, and the peak
On January 9, 2020 Eli Lilly and Strateos unveiled the Lilly Life Sciences Studio in San Diego: 11,500 square feet, more than 100 instruments, storage for over five million compounds, built from a $90 million commitment Lilly made in 2017. Lilly designed it, Strateos ran it and sold access to outsiders, and the release called it “the first-ever cloud laboratory to integrate automated biology and chemistry research capabilities in a closed-loop system.”
In June 2021 Strateos raised $56.1 million led by DCVC and Lux, with Lilly participating, taking reported total funding to around $90 million at an estimated $200 million valuation. Forbes counted some 100 customers including Amgen, AbbVie, Ginkgo Bioworks and DARPA, and a San Diego floor that the head of product compared to a silicon wafer foundry.
The pivot, and the quiet
On April 18, 2023 Strateos announced a shift away from running its own cloud labs and toward deploying its LodeStar software inside customer facilities, plus what it called a reorganization to adjust its staffing structure. That is the last announcement this review could find. In September 2024 Lilly sold the Life Sciences Studio to Arctoris, a British contract research organization, which moved the platform from San Diego to Oxford.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Peer-reviewed output | Staff with a Transcriptic or Strateos affiliation appear in SLAS Technology (2018), ACS Synthetic Biology (2022), Synthetic Biology (2022 and 2023), iScience (2020 and 2021), Nature Protocols (2021) and the Journal of Cheminformatics (Nov 14, 2024). Outside groups used the platform too. | Public record |
| DARPA work | Two Synthetic Biology papers state that a remote robotic lab at Strateos executed parameterized protocols under DARPA’s Synergistic Discovery and Design program. | Public record |
| Ginkgo Bioworks license | Ginkgo’s 10-K discloses a collaboration signed October 2, 2017 and restated April 20, 2021 granting a perpetual, royalty-free license to the software. “The Strateos Collaboration Agreement expired in 2022 and we retain a license to use Strateos’ software.” | Public record |
| The Lilly lab | Launched January 2020, operated by Strateos. Sold by Lilly to Arctoris in September 2024 and relocated to Oxford, England. | Independent |
| Customers and throughput | Some 100 customers and a facility “capable of doing 190,000 experiments per day” were reported by Forbes in 2021, sourced to the company. No customer list, contract value or revenue figure has been published. | Company-stated |
| The first online equity round | Transcriptic said more than 60 accredited investors put in $150,000 through AngelList and SecondMarket, the first significant equity round raised online. The Form D filed days earlier reports 39 investors and $147,993 sold. | Differs from the filing |
| Patents | No assignee patent list could be retrieved for either name from the free patent databases reachable during this review. A research gap, not a finding that none exist. | Not retrieved |
| Current status | strateos.com and transcriptic.com resolve to one site whose copy is interrupted by unrelated promotional text about rolling papers and whose metric counters render as zeros. No announcement after April 18, 2023 and no filing under the Strateos, Inc. CIK since 2019. No record of an acquisition, dissolution or bankruptcy was located. | Not found |
Read plainly: the technology worked well enough to put a Transcriptic or Strateos line into a decade of papers, to persuade Eli Lilly to hand over a robotic lab, and to give Ginkgo a license it still holds. The commercial proof never appeared: no named customer, no contract value, no revenue number.
What to watch
- Any filing under the Strateos, Inc. CIK. Nothing has appeared there since July 2019.
- Where the LodeStar software and the Menlo Park work cells ended up.
- The November 2024 IRAK1 paper in the Journal of Cheminformatics, which used Strateos automated labs alongside an AI screening model. It is the most recent published evidence of the platform in use.
- Max Hodak now runs Science Corporation, a brain interface company. The Transcriptic thesis, that an instrument should be addressable by code, followed him.
In their words
“Borrowing the metaphor from what cloud computing had done to software, the idea of creating a robotic cloud laboratory for biology seemed obvious.”
Max Hodak, founder, personal site · Founder-stated
“Right now basic research is all done by hand, by grad students or lab techs standing at benches all day long doing really boring manual labor.”
Max Hodak, to TechCrunch, December 2012 · Interview
“Transcriptic will hopefully do for biotech startups what AWS has done for web startups.”
Y Combinator blog, December 2014 · Accelerator
“We are thrilled to help build a globally impactful and historic company.”
Josh Wolfe, Lux Capital, merger release, June 2019 · Company release
“Labs should be thought of as data engines.”
Mark Fischer-Colbrie, CEO, to Forbes, June 2021 · Independent
“When you are inside this building, you feel like you are in a silicon wafer foundry or a data center.”
Ben Miles, head of product, to Forbes, June 2021 · Independent
“The results have not lived up to expectations.”
Stefan Golas, on cloud labs generally, December 2024 · Independent
Related companies
Sources
- Public recordForm D, Strateos, Inc., CIK 0001781338
- Public recordForm D, SecondMarket Transcriptic Fund
- Public recordForm D, AVGSF - Strateos 2021
- Public recordGinkgo Bioworks Form 10-K, Strateos agreement
- Public recordBionano Genomics proxy, Linney biography
- Public recordAchieving Reproducibility and Closed-Loop Automation
- Public recordAccelerated hit identification in IRAK1
- IndependentTranscriptic Receives $1.2M In Seed Funding
- IndependentTranscriptic Lands $8.5 Million In Series A
- IndependentTranscriptic raises $13.4 million
- IndependentRemote-Controlled Labs? Strateos Raises $56 Million
- IndependentStrateos scores $56M for its SmartLab platform
- IndependentEli Lilly sells Life Sciences Studio lab to Arctoris
- IndependentWhat Happened to Cloud Labs?
- CompanyStrateos combines Transcriptic and 3Scan
- CompanyLilly and Strateos launch a robotic cloud lab
- CompanyStrateos Announces Strategic Shift to On-Site Cloud Labs
- FounderMax Hodak, about page
- AcceleratorTranscriptic for YC biotech startups
- Companystrateos.com and transcriptic.com
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
